Retrospective review of megestrol use for weight loss in an elderly veteran population
OBJECTIVE: Evaluate the efficacy of megestrol acetate therapy for nonmalignancy and/or non-AIDS-related weight loss in the elderly.
DESIGN: Retrospective chart review.
SETTING: Inpatients or outpatients at the West Palm Beach Veterans Affairs Medical Center.
PATIENTS: Two inclusion criteria were applied: patients older than 65 years and patients initiated on megestrol therapy from January 1 to December 31, 2002. All eligible patients meeting the above criteria were eligible for inclusion in the study. Patients who had a diagnosis of malignancy and/or AIDS, no baseline weight, no follow-up weights, no record of laboratory values, and/or were receiving enteral or parenteral nutrition available at the West Palm Beach Veterans Affairs Medical Center, were excluded. Patients who received megestrol therapy for less than one week also were excluded.
MEASUREMENTS: Weight loss in the previous six months, baseline weight, follow-up weights at 3, 6, 9, and 12 months after megestrol initiation, baseline and follow-up albumin for 12 months after megestrol initiation, and any adverse effects from megestrol.
RESULTS: Fifty-seven patients (males 56, females 1) were included. The average age was 78.5 years old. The average duration of therapy was 3.2 months, and the average starting dose of megestrol was 436 mg per day. At baseline, patients were, on average, 102% of their ideal body weight. Baseline measurement of albumin was obtained in 89% (N = 23) of patients. Six out of 23 (26%) patients had a baseline albumin less than 3 g/dL. The average baseline albumin was 3.6. Weight loss in the six months prior to megestrol initiation occurred in 63% of patients. Over the 12-month follow-up period, the percentage of patients who gained weight was 40%, lost weight was 49%, and had no change in weight was 11%. There were no differences in baseline characteristics between the patients who did or did not gain weight during the 12-month period after megestrol initiation. No documented adverse side effects were attributed to megestrol.
CONCLUSION: Patients both gained and lost weight when receiving megestrol therapy. There was no difference between the patients who did or did not gain weight using objective measures of weight loss.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2005 |
|---|---|
| Erschienen: |
2005 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists - 20(2005), 4 vom: 28. Apr., Seite 301-5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kennedy, Deborah H [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 21.04.2006 Date Revised 09.11.2019 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM161381863 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM161381863 | ||
| 003 | DE-627 | ||
| 005 | 20231223092052.0 | ||
| 007 | tu | ||
| 008 | 231223s2005 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0538.xml |
| 035 | |a (DE-627)NLM161381863 | ||
| 035 | |a (NLM)16548634 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kennedy, Deborah H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Retrospective review of megestrol use for weight loss in an elderly veteran population |
| 264 | 1 | |c 2005 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2006 | ||
| 500 | |a Date Revised 09.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a OBJECTIVE: Evaluate the efficacy of megestrol acetate therapy for nonmalignancy and/or non-AIDS-related weight loss in the elderly | ||
| 520 | |a DESIGN: Retrospective chart review | ||
| 520 | |a SETTING: Inpatients or outpatients at the West Palm Beach Veterans Affairs Medical Center | ||
| 520 | |a PATIENTS: Two inclusion criteria were applied: patients older than 65 years and patients initiated on megestrol therapy from January 1 to December 31, 2002. All eligible patients meeting the above criteria were eligible for inclusion in the study. Patients who had a diagnosis of malignancy and/or AIDS, no baseline weight, no follow-up weights, no record of laboratory values, and/or were receiving enteral or parenteral nutrition available at the West Palm Beach Veterans Affairs Medical Center, were excluded. Patients who received megestrol therapy for less than one week also were excluded | ||
| 520 | |a MEASUREMENTS: Weight loss in the previous six months, baseline weight, follow-up weights at 3, 6, 9, and 12 months after megestrol initiation, baseline and follow-up albumin for 12 months after megestrol initiation, and any adverse effects from megestrol | ||
| 520 | |a RESULTS: Fifty-seven patients (males 56, females 1) were included. The average age was 78.5 years old. The average duration of therapy was 3.2 months, and the average starting dose of megestrol was 436 mg per day. At baseline, patients were, on average, 102% of their ideal body weight. Baseline measurement of albumin was obtained in 89% (N = 23) of patients. Six out of 23 (26%) patients had a baseline albumin less than 3 g/dL. The average baseline albumin was 3.6. Weight loss in the six months prior to megestrol initiation occurred in 63% of patients. Over the 12-month follow-up period, the percentage of patients who gained weight was 40%, lost weight was 49%, and had no change in weight was 11%. There were no differences in baseline characteristics between the patients who did or did not gain weight during the 12-month period after megestrol initiation. No documented adverse side effects were attributed to megestrol | ||
| 520 | |a CONCLUSION: Patients both gained and lost weight when receiving megestrol therapy. There was no difference between the patients who did or did not gain weight using objective measures of weight loss | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Ward, Ceressa T |e verfasserin |4 aut | |
| 700 | 1 | |a Salvig, Brent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists |d 1997 |g 20(2005), 4 vom: 28. Apr., Seite 301-5 |w (DE-627)NLM089792254 |x 2331-0936 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2005 |g number:4 |g day:28 |g month:04 |g pages:301-5 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2005 |e 4 |b 28 |c 04 |h 301-5 | ||